CAR-T cell simultaneously targeting BCMA and CD38 and preparation method thereof

Abstract

The invention belongs to the field of biological medicine, and discloses a CAR-T cell simultaneously targeting BCMA and CD38 and a preparation method thereof, the method comprises the step of infecting a T cell with a recombinant lentivirus, and the recombinant lentivirus contains nucleic acid molecules encoding BCMA and CD38 or is prepared through an expression vector containing the nucleic acid molecules. According to the present invention, the simultaneous BCMA and CD38 targeting can effectively avoid the immune escape caused by BCMA down-regulation or loss so as to achieve the good treatment effect.

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to CAR-T cells that simultaneously target BCMA and CD38, and a preparation method and application thereof. Background Art

[0002] Multiple myeloma (MM) is one of the most common hematological malignancies, with extremely high morbidity and mortality (Bray et al., 2024, Cowan et al., 2018). In recent years, emerging drugs such as immunomodulatory drugs, proteasome inhibitors and CD38 monoclonal antibodies have improved the prognosis of MM patients, with the 5-year overall survival rate increasing from 30% to 60% (Kumar et al., 2008, Turesson et al., 2010, Ozaki et al., 2014), but MM is still incurable and new treatment strategies are urgently needed.

[0003] Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy is a new type of immunotherapy that has great potential in long-term disease control of some hematological malignancies (Schuster et al., 2017, Turtle et al., 2017). This therapy uses genetic engineering to construct a chimeric antigen receptor expression vector to transfect T cells, so that the T cell surface expresses a chimeric receptor that can recognize target cells, thereby specifically recognizing the target cell surface antigen and achieving the effect of specific killing of the target cell.

[0004] B-cell maturation antigen (BCMA) belongs to the tumor necrosis factor receptor superfamily and is mainly expressed on normal plasma cells and malignant plasma cells (PCs) as well as a small number of mature B cells and plasmacytoid dendritic cells. BCMA is not expressed on hematopoietic stem cells or non-hematopoietic stem cells, but is expressed on most MM cells. Therefore, it is considered to be an ideal target for CAR-T cell therapy in MM (Carpenter et al., 2013, Tai et al., 2014). However, although BCMA-targeted CAR-T cells have achieved excellent clinical remission rates (81% to 97%) in MM patients, 45% of patients still relapse (Raje et al., 2019, Brudno et al., 2018). After BCMA-targeted CAR-T cell therapy, BCMA downregulation or loss was observed in 4% to 33% of patients with progression (Munshi et al., 2021, Mikkilineni et al., 2019), which may be one of the reasons limiting the durable response provided by CAR-T cell therapy.

[0005] The construction of bispecific CAR-T cells may be an effective strategy to reduce the limitations of BCMA-targeted CAR-T and enhance the function of CAR-T cells (Zah et al., 2020). CD38 is a single-chain type II transmembrane glycoprotein that mediates signal transduction in lymphocytes and bone marrow cells. CD38 is highly expressed on myeloma cells, but its expression level in normal lymphocytes, bone marrow cells and some non-hematopoietic tissues is relatively low, making it a potential target for the treatment of multiple myeloma.

[0006] In view of the problem of antigen downregulation and escape in the current BCMA single-target CAR-T cell therapy, which leads to a high tumor recurrence rate, it is necessary to provide CAR-T cells that simultaneously target BCMA and CD38 to enhance the efficacy of CAR-T cell therapy in MM and provide a new strategy for the effective prevention and treatment of MM recurrence / metastasis. Summary of the invention

[0007] In response to the problem of cancer recurrence due to low expression or loss of BCMA in single-target BCMA-CAR-T cell therapy, the purpose of the present invention is to provide bispecific CAR-T cells that can simultaneously target BCMA and CD38, in the hope of reducing the immune escape of tumor cells and reducing the recurrence rate.

[0008] The purpose of the present invention and the solution to its technical problem can be achieved by adopting the following technical solutions.

[0009] In a first aspect, the present invention provides a chimeric antigen receptor (BCMA-CD38-CAR) that simultaneously targets BCMA and CD38, comprising the following elements:

[0010] 1) signal peptide region, 2) anti-BCMA heavy chain region; 3) linker 1; 4) anti-BCMA light chain region; 5) linker 2; 6) anti-CD38 antibody region; 7) hinge region; 8) transmembrane region; 9) intracellular signal co-stimulatory region; and 10) intracellular signal stimulatory region,

[0011] The amino acid sequence of the anti-CD38 antibody region is shown in any one of SEQ ID NOs: 3-12.

[0012] In an embodiment of the present invention, the positions of the anti-BCMA heavy chain region and the anti-BCMA light chain region can be interchanged.

[0013] In an embodiment of the present invention, the positions of the anti-CD38 antibody region and the anti-BCMA antibody region comprising the anti-BCMA heavy chain region, the anti-BCMA light chain and the linker can be interchanged.

[0014] In an embodiment of the present invention, the signal peptide region can be a signal peptide of a mammalian cell surface protein. In a specific embodiment, the signal peptide region is a human albumin signal peptide, a human insulin signal peptide or a mouse IgG kappa signal peptide, and its amino acid sequence is shown in SEQ ID NO: 13, 14 or 15.

[0015] In an embodiment of the present invention, the amino acid sequence of the anti-BCMA heavy chain region is shown in SEQ ID NO: 1.

[0016] In an embodiment of the present invention, the amino acid sequence of the anti-BCMA light chain region is shown in SEQ ID NO: 2.

[0017] In an embodiment of the present invention, the amino acid sequence of linker 1 between the heavy chain and the light chain of the anti-BCMA antibody is shown in SEQ ID NO:16.

[0018] In an embodiment of the present invention, the amino acid sequence of linker 2 between the anti-BCMA antibody and the anti-CD38 antibody is shown in SEQ ID NO:17.

[0019] In an embodiment of the present invention, the hinge region may be the hinge region of human CD8α or human CD28. Preferably, the hinge region is the hinge region of human CD8α, whose amino acid sequence is shown in SEQ ID NO:18.

[0020] In an embodiment of the present invention, the transmembrane region may be the transmembrane region of human CD8α or human CD28. Preferably, the transmembrane region is the transmembrane region of human CD8α, and its amino acid sequence is shown in SEQ ID NO:19.

[0021] In an embodiment of the present invention, the amino acid sequence of the intracellular co-stimulatory region is shown in SEQ ID NO:20.

[0022] In an embodiment of the present invention, the amino acid sequence of the intracellular stimulatory region is shown in SEQ ID NO:21.

[0023] In a second aspect, the present invention provides a nucleic acid molecule encoding a chimeric antigen receptor (BCMA-CD38-CAR) that simultaneously targets BCMA and CD38.

[0024] In a third aspect, the present invention provides an expression vector comprising a nucleic acid molecule encoding a chimeric antigen receptor (BCMA-CD38-CAR) that simultaneously targets BCMA and CD38.

[0025] In a fourth aspect, the present invention provides a recombinant lentivirus, which comprises the nucleic acid molecule of the second aspect or is prepared by the expression vector of the third aspect.

[0026] In a fifth aspect, the present invention provides a method for preparing a recombinant lentivirus, comprising co-transfecting a mammalian host cell with the expression vector of the third aspect and a helper plasmid to obtain a recombinant lentivirus.

[0027] In the embodiments of the fifth aspect, the mammalian host cells may be, but are not limited to, HEK293 cells, human PER.C6 cells, human Hela cells, mouse CHO cells, etc., preferably HEK293 cells.

[0028] In an embodiment of the fifth aspect, the helper plasmid may be pMDLG-pRRE-Kana, pMD2G-Kana, and pRSV-REV-Kana.

[0029] In a sixth aspect, the present invention provides CAR-T cells (BCMA-CD38-CAR-T cells) that simultaneously target BCMA and CD38, which cells express the chimeric antigen receptor (BCMA-CD38-CAR) that simultaneously targets BCMA and CD38 of the first aspect of the present invention.

[0030] In a seventh aspect, the present invention provides a method for preparing the BCMA-CD38-CAR-T cells of the sixth aspect, comprising infecting T cells with the recombinant lentivirus of the fifth aspect.

[0031] In a specific embodiment of the seventh aspect, the method for preparing the BCMA-CD38-CAR-T cells of the sixth aspect comprises the following steps:

[0032] (1) constructing a recombinant lentiviral expression vector carrying a nucleotide sequence encoding BCMA-CD38-CAR;

[0033] (2) transfecting host cells with the above-mentioned recombinant lentiviral expression vector and helper plasmid to prepare a recombinant lentivirus that can infect T cells;

[0034] (3) Isolate peripheral blood mononuclear cells (PBMCs) from peripheral blood provided by the donor, and use magnetic beads to separate and activate T cells;

[0035] (4) Infecting T cells with the recombinant lentivirus obtained in step (2) to produce BCMA-CD38-CAR-T cells expressing BCMA-CD38-CAR.

[0036] In an embodiment of the seventh aspect, the helper plasmid may be pMDLG-pRRE-Kana, pMD2G-Kana, and pRSV-REV-Kana.

[0037] In a further embodiment, the method may further comprise the following steps after step (4):

[0038] (5) culturing the cells obtained in step (4) in vitro;

[0039] (6) amplifying the cells obtained in step (5) in large quantities; and

[0040] (7) Collect BCMA-CD38-CAR-T cells.

[0041] In an eighth aspect, the present invention provides a disease treatment drug, which comprises the nucleic acid molecule of the second aspect of the present invention, the expression vector of the third aspect of the present invention, the recombinant lentivirus of the fourth aspect of the present invention, or the BCMA-CD38-CAR-T cell of the sixth aspect of the present invention.

[0042] In a ninth aspect, the present invention provides the use of the above-mentioned nucleic acid molecule, the above-mentioned expression vector, the above-mentioned recombinant lentivirus or the above-mentioned BCMA-CD38-CAR-T cell in the preparation of a drug for treating a disease.

[0043] In an embodiment of the present invention, the disease refers to a disease characterized by high expression of BCMA and / or CD38 molecules on the cell surface. In a specific embodiment, the disease can be multiple myeloma, lymphoma, leukemia, systemic lupus erythematosus, Sjögren's syndrome, etc.

[0044] In an embodiment of the present invention, CAR represents a chimeric antigen receptor, BCMA-CAR represents a chimeric antigen receptor targeting BCMA, BCMA-CD38-CAR represents a chimeric antigen receptor simultaneously targeting BCMA and CD38, CAR-T cells represent chimeric antigen receptor T cells, BCMA-CAR-T cells represent chimeric antigen receptor T cells targeting BCMA, and BCMA-CD38-CAR-T cells represent T cells simultaneously targeting BCMA and CD38.

[0045] Compared with the prior art, the present invention has obvious beneficial effects. By means of the above technical solution, the present invention has at least the following beneficial technical effects:

[0046] 1. The present invention uses BCMA and CD38 as targets to obtain monoclonal antibody gene sequences that specifically recognize CD38 and BCMA, which are unique and distinctive. The BCMA-CD38-CAR-T cells constructed and prepared on this basis are also unique and distinctive in recognizing CD38-positive and BCMA-positive tumor cells.

[0047] 2. BCMA-CD38-CAR-T cells simultaneously target two surface markers of multiple myeloma, CD38 and BCMA, which can effectively avoid the problem of antigen escape and prevent tumor recurrence caused by the loss of a single target.

[0048] 3. The killing activity of BCMA-CD38-CAR-T cells against the myeloma cell line MM.1S-GFP is significantly higher than that of unmodified T cells and single-target BCMA-CAR-T cells. Using a low dose of effector cells (0.2 times-0.4 times the number of target cells), the myeloma cell line MM.1S-GFP can be effectively killed, and it has excellent myeloma targeted killing activity.

[0049] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention, it can be implemented in accordance with the contents of the specification. In order to make the above and other purposes, features and advantages of the present invention more obvious and easy to understand, the following specifically cites a preferred embodiment and describes it in detail with the accompanying drawings as follows. BRIEF DESCRIPTION OF THE DRAWINGS

[0050] Figure 1 It is a schematic diagram of the structure of BCMA-CD38-CAR and BCMA-CAR of the present invention, wherein (A) and (C) respectively represent the primary sequence diagram of BCMA-CD38-CAR and the three-dimensional structure schematic diagram after CAR protein expression, and (B) represents the primary sequence diagram of BCMA-CAR.

[0051] Figure 2These are the CAR positivity test results of BCMA-CD38-CAR-T cells and BCMA-CAR-T cells provided by the present invention on the 5th day and the 7th day after viral transfection.

[0052] Figure 3 The 24-hour in vitro killing results of BCMA-CD38-CAR-T cells, BCMA-CAR-T cells and T cells provided by the present invention on MM.1S-GFP target cells are compared. The horizontal axis is the effect-target ratio, and the vertical axis is the killing rate.

[0053] Figure 4 The 24-hour in vitro killing results of BCMA-CD38-CAR-T cells, BCMA-CAR-T cells and T cells provided by the present invention on MM.1S-GFP target cells are compared. The horizontal axis is the effect-target ratio, and the vertical axis is the number of remaining target cells. DETAILED DESCRIPTION

[0054] The preferred embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that the following examples are provided only for the purpose of illustration and are not intended to limit the scope of protection of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention, and all of these modifications and substitutions fall within the scope of the claims of the present invention.

[0055] The experimental methods used in the following examples are all conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.

[0056] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the examples are all based on conventional experimental conditions, such as Sambrook et al. Molecular Cloning: a Laboratory Manual (Sambrook J & Russell DW, Molecular Cloning: a Laboratory Manual, 2012), or the conditions recommended by the manufacturer's instructions.

[0057] Materials and methods

[0058] 1. Design and construction of plasmids encoding BCMA-CD38-CAR and BCMA-CAR

[0059] The plasmid encoding BCMA-CD38-CAR was synthesized by Shenzhen BGI Co., Ltd., and the plasmid contained nucleotide sequences encoding the following elements in order from 5' to 3' direction of the CAR structure: signal peptide region (SEQ ID NO: 13, 14 or 15), anti-BCMA heavy chain region (SEQ ID NO: 1), linker 1 (SEQ ID NO: 16), anti-BCMA light chain region (SEQ ID NO: 2), linker 2 (SEQ ID NO: 17), anti-CD38 antibody (SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12), hinge region (SEQ ID NO: 18), transmembrane region (SEQ ID NO: 19), intracellular signal co-stimulatory region (SEQ ID NO: 20) and intracellular signal stimulatory region (SEQ ID NO: 21). The plasmid was cloned into the lentiviral master plasmid pMSGV-IRES (Shanghai Newpro Biotechnology Co., Ltd., catalog number: V000092) to obtain a plasmid encoding BCMA-CD38-CAR, which is called pMSGV-sBCMA-CD38, and is a recombinant lentiviral expression vector in virus packaging. In the present invention, the positions of the anti-BCMA heavy chain region and the anti-BCMA light chain region can be interchanged, and the anti-CD38 antibody region can be interchanged with the anti-BCMA antibody region (including heavy chain, light chain and linker), such as Figure 1 As shown in (A).

[0060] In order to compare with BCMA-CD38-CAR, the present invention also constructed a plasmid encoding BCMA-CAR, which sequentially comprises nucleotide sequences encoding the following elements: a signal peptide region (SEQ ID NO: 13), an anti-BCMA heavy chain region (SEQ ID NO: 1), a linker 1 (SEQ ID NO: 16), an anti-BCMA light chain region (SEQ ID NO: 2), a hinge region (SEQ ID NO: 18), a transmembrane region (SEQ ID NO: 19), an intracellular signal co-stimulatory region (SEQ ID NO: 20) and an intracellular signal stimulatory region (SEQ ID NO: 21), the structure is as follows Figure 1 The plasmid was cloned into the lentiviral master plasmid pMSGV-IRES to obtain a plasmid encoding BCMA-CAR, which is called pMSGV-BCMA and is a recombinant lentiviral expression vector in virus packaging.

[0061] 2. Preparation of recombinant lentivirus

[0062] The main plasmid pMSGV-sBCMA-CD38 or pMSGV-BCMA is co-transfected with three auxiliary plasmids into mammalian cells to prepare recombinant lentivirus that can infect T cells. The specific steps are as follows:

[0063] 2.1. Prepare a culture area of ​​525 cm 2 Cell culture flask, seeded with 6×10 7 WayneLVPro HEK293 cells (SuspensionAdapted) (Zhongshan Kangsheng Biotechnology Co., Ltd., Catalog No. A23109, hereinafter referred to as 293T cells) were added with complete culture medium containing DMEM (Situofan Biotechnology (Hangzhou) Co., Ltd., Catalog No.: SH30243.01) and 10% FBS (Situofan Biotechnology (Hangzhou) Co., Ltd., Catalog No.: SH30256.01), and cultured in a 37°C, 5% CO2 cell culture incubator overnight.

[0064] 2.2. Take 576 μL of 1 mg / mL PEI (Merck Biotechnology Co., Ltd., Catalog No.: 937762), add it to 4 mL OPTI-MEM (Thermo Fisher Scientific Biotechnology Co., Ltd., Catalog No.: 11058021), mix by pipetting, and let stand at room temperature for 20 min.

[0065] 2.3. Add 54 μg of the main plasmid pMSGV-sBCMA-CD38 or pMSGV-BCMA and three auxiliary plasmids, namely 16 μg pMD2G-Kana (Changsha Abiwei Biotechnology Co., Ltd., Catalog No.: HG-VMA0648), 16 μg pRSV-REV-Kana (Changsha Abiwei Biotechnology Co., Ltd., Catalog No.: HG-VMA0370) and 48 μg pMDLG-pRRE-Kana (Changsha Abiwei Biotechnology Co., Ltd., Catalog No.: HG-VMA0374) into 4 mL OPTI-MEM and mix well.

[0066] 2.4. Add the PEI and OPTI-MEM mixed solution in step 2.2 to the solution in step 2.3, mix well, and let stand at room temperature for 20 minutes.

[0067] 2.5. Add 32 mL of DMEM + 10% FBS complete medium to the solution in step 2.4 and mix well.

[0068] 2.6. Aspirate the culture medium in the 293T cell culture flask and add the culture medium prepared in step 2.5.

[0069] 2.7.293T cells were cultured in a 37°C, 5% CO2 incubator for 6 h, and then the culture medium (DMEM+10% FBS+0.5% sodium butyrate (Sigma-Aldrich (Shanghai) Trading Co., Ltd., Cat. No.: 303410)) was replaced and culture was continued for 48 h.

[0070] 2.8. Centrifuge the above culture medium, take the supernatant, filter it through 0.22 μm and place it at -20℃ for 30 min.

[0071] 2.9. Centrifuge the supernatant in step 2.8 at 1800g at 4°C for 2h, discard the supernatant, resuspend the virus particles in 500μL KBM581 (Corning (Shanghai) Management Co., Ltd., Catalog No.: 88-581-CM) serum-free culture medium, and store at -80°C.

[0072] 3. Recombinant Lentivirus Titer Detection

[0073] 3.1. Take Jurkat cells (purchased from ATCC: MD130) after resuscitation culture for 2 generations and centrifuge at 400g for 10 minutes.

[0074] 3.2. Resuspend the cells to 2×10 in RPMI1640 medium (Situofan Biotechnology (Hangzhou) Co., Ltd., Catalog No.: SH30809-01). 6 cells / mL, 48-well plate, 2×10 5 cells / well.

[0075] 3.3. Take 100 μL of the recombinant lentivirus prepared in step 2 diluted 200 times with RPMI1640 and add it to the plated cells and mix thoroughly.

[0076] 3.4.6 hours later, add 800 μL of RPMI1640 + 10% FBS complete culture medium and culture in a 37°C, 5% CO2 cell culture incubator.

[0077] 3.5. Perform flow cytometry detection after 48 hours.

[0078] 4. T cell isolation and activation

[0079] 4.1. Take 15 mL of peripheral blood from a healthy donor under sterile conditions, let it stand at room temperature for 30 minutes, centrifuge at 400 g for 30 minutes, and aspirate the upper plasma for later use.

[0080] 4.2. Dilute the lower layer of blood cells with PBS at a ratio of 1:1 and mix well. Carefully add human peripheral blood lymphocyte separation solution (Tianjin Haoyang Biological Products Co., Ltd., catalog number: LTS1077) to the upper layer at a ratio of 1:2 and centrifuge at 300g for 10 minutes.

[0081] 4.3. After centrifugation, aspirate the buffy coat layer above the separation solution into a new centrifuge tube, add PBS to wash the buffy coat layer, centrifuge at 300g for 10 minutes, and discard the supernatant to obtain PBMC (Peripheral Blood Mononuclear Cell).

[0082] 4.4. Isolate T lymphocytes by magnetic bead sorting using CD3 Microbeads (Human) (Miltenyi Biotec, Cat. No. 130-050-101) and count the cells.

[0083] 4.5. Take the CD3 obtained by sorting + T cells were centrifuged at 300 g for 10 min at 4°C.

[0084] 4.6. Discard the supernatant and add X-VIVO containing 40 IU / mL human IL-2 (Suzhou Nearshore Protein Technology Co., Ltd., catalog number: GMP-CD66) TM 15 serum-free culture medium (Lonza (China) Investment Co., Ltd., catalog number: DL-102), and the cell concentration was adjusted to 1×10 6 cells / mL.

[0085] 4.7. According to Dynabeads TM Mouse T-Activator CD3 / CD28 for T-Cell Expansion and Activation (Thermo Fisher Scientific, Cat. No. 11452D) was used to activate T cells as described in the instructions and inoculated in 24-well cell culture plates at a concentration of 1×10 6 cells / mL, 1 mL / well; culture in a cell culture incubator for 48 hours to obtain activated unmodified T cells.

[0086] 5. Preparation of CAR-T cells

[0087] 5.1. Take a 24-well plate, isolate and activate T cells for 48 hours, add 30 μL of 1 mg / mL protamine (Sigma-Aldrich (Shanghai) Trading Co., Ltd., Catalog No.: P4020) to each well, and mix by pipetting.

[0088] 5.2. According to MOI=3, calculate the required amount of virus. The calculation formula is as follows: Required amount of virus (mL) = (MOI*number of cells) / virus titer. According to the calculation results, add BCMA-CD38-CAR and BCMA-CAR lentivirus into a 24-well plate respectively and mix thoroughly.

[0089] 5.3. Seal the four sides of the 24-well plate with sealing film, centrifuge at 1000g for 30 minutes, and culture in a cell culture incubator at 37°C and 5% CO2.

[0090] 5.4. All samples were stained with PE-BCMA (Beijing Sino Biological Science and Technology Co., Ltd., Catalog No.: 10620-H02H) and FITC-CD38 (Beijing Sino Biological Science and Technology Co., Ltd., Catalog No.: 10818-H08H-F) antigens, and CAR expression was detected by flow cytometry.

[0091] 6. In vitro killing experiment of CAR-T cells on target cells

[0092] MM.1S cells (Cell Bank of the Chinese Academy of Sciences, catalog number: SCSP-5017) were injected with GFP protein and transformed into MM.1S-GFP cells as target cells. BCMA-CD38-CAR-T cells, BCMA-CAR-T cells and unmodified T cells were used as effector cells for killing activity determination. The specific steps are as follows:

[0093] 6.1. Adjust the target cells to the logarithmic growth phase and subculture them twice before conducting the experiment.

[0094] 6.2. Adjust the target cell density to 1×10 6 2 mL per well was inoculated in a 6-well plate.

[0095] 6.3. Set the ratio of effector cells to target cells to 0.2 and 0.4 respectively, and adjust the concentration of effector cells to 1×10 6 cells / mL and added into the target cell wells for co-culture.

[0096] 6.4. Adjust the concentration of unmodified T cells to 1×10 6 cells / mL. According to the amount of effector cells added in the experimental group, unmodified T cells were added to the target cell wells as controls, and target cell wells without effector cells were used as blank controls.

[0097] 6.5. After the above 6-well plate was placed in a 37°C, 5% CO2 cell culture incubator for 24 hours, the culture medium volume and cell concentration in each well were calculated.

[0098] 6.6 All samples were subjected to flow cytometry and the positive rate of target cells was detected through the FITC channel.

[0099] Results and Discussion

[0100] According to the above method, BCMA-CAR-T cells and 40 types of BCMA-CD38-CAR-T cells were constructed. According to the different positions of the anti-BCMA heavy chain region and anti-BCMA light chain region, the anti-CD38 antibody region and the anti-BCMA antibody region (including heavy chain, light chain and linker) in CAR (such as Figure 1 (A) shows the four structures of BCMA-CD38-CAR a / b / c / d, referred to as a / b / c / d in Table 1 below), and different sequences of the anti-CD38 antibody region, a total of 40 BCMA-CD38-CAR-T cells were constructed. Table 1 lists these 40 cells.

[0101] Table 1. 40 types of BCMA-CD38-CAR-T cells constructed by the present invention

[0102]

[0103]

[0104] *. The first column indicates the killing rate of MM.1s-GFP target cells after 24 hours when the effector-target ratio is 0.2, and the second column indicates the killing rate of MM.1s-GFP target cells after 24 hours when the effector-target ratio is 0.4.

[0105] The experimental results showed that the BCMA positivity rates of these 40 types of BCMA-CD38-CAR-T cells were all higher than 85%, and the CD38 positivity rates were all higher than 80% (see Table 1). Figure 2 It shows that the BCMA-CD38-CAR-T cells with cell number 15 (i.e., the anti-CD38 antibody region sequence is SEQ ID NO: 6, and the CAR structure is c) have a BCMA and CD38 positivity rate higher than 80% on the 5th and 7th days after viral transfection; the BCMA positivity rate of BCMA-CAR-T cells is also higher than 80%.

[0106] In the in vitro killing experiment of CAR-T cells on target cells, these 40 types of BCMA-CD38-CAR-T cells also showed similar killing effects (see Table 1). Figure 3 and Figure 4 The results showed that under lower effector-target ratio conditions, BCMA-CD38-CAR-T cells with cell number 15 still had a significant killing effect on MM.1s-GFP target cells, and the killing effect was stronger than that of T cells expressing BCMA-CAR alone; when the effector-target ratio was 0.4, the tumor killing abilities of BCMA-CD38-CAR-T cells and T cells expressing BCMA-CAR were 85.7% and 77.6%, respectively.

[0107] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the above embodiments, it should be understood by those skilled in the art that the technical solutions described in the above embodiments may be modified, or some or all of the technical features thereof may be replaced by equivalents without departing from the concept, spirit and scope of the present invention; and these modifications or replacements fall within the scope of protection claimed in the claims of the present invention.

[0108] References

[0109] BRAY,F.,LAVERSANNE,M.,SUNG,H.,FERLAY,J.,SIEGEL,R.L.,SOERJOMATARAM,I.&JEMAL,A.(2024),"Global cancer statistics 2022:GLOBOCAN estimates of incidenceand mortality worldwide for 36cancersin 185countries.",CA:a cancerjournal forclinicians,Vol.74 No.3,pp.229-263.

[0110] BRUDNO,J.N.,MARIC,I.,HARTMAN,S.D.,ROSE,J.J.,WANG,M.,LAM,N.,STETLER-STEVENSON,M.,SALEM,D.,YUAN,C.,PAVLETIC,S.,KANAKRY,J.A.,ALI,S.A.,MIKKILINENI,L.,FELDMAN,S.A.,STRONCEK,D.F.,HANSEN,B.G.,LAWRENCE,J.,PATEL,R.,HAKIM,F.,GRESS,R.E.&KOCHENDERFER,J.N.(2018),"TCells Genetically Modified to Express anAnti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions ofPoor-Prognosis Relapsed Multiple Myeloma.",Journal of clinical oncology:official journal of the American Society of Clinical Oncology,Vol.36No.22,pp.2267-2280.

[0111] CARPENTER,RO,EVBUOMWAN,MO,PITTALUGA,S.,ROSE,JJ,RAFFELD,M.,YANG,S.,GRESS,RE,HAKIM,FT&KOCHENDERFER,JN(2013),"B-cell maturation antigens a promising target for adoptive T-cell therapy of multiple myeloma." forCancer Research,Vol.19No.8,pp.2048-60.

[0112] COWAN,AJ,ALLEN,C.,BARAC,A.,BASALEEM,H.,BENSENOR,I.,CURATE,MP,FOREMAN,K.,GUPTA,R.,H ARVEY,J.,HOSGOOD,HD,JAKOVLJEVIC,M.,KHADER,Y.,LINN,S.,LAD,D.,MANTOVANI,L.,NONG,VM,M OKDAD,A.,NAGHAVI,M.,POSTMA,M.,ROSHANDEL,G.,SHACKELFORD,K.,SISAY,M.,NGUYEN,CT,TRAN,TT,XUAN,BT,UKWAJA,KN,VOLLSET,SE,WEIDERPASS,E.,LIBBY,EN&FITZMAURICE,C.(2018),"Global Burden of MultipleMyeloma:A Systematic Analysis forthe Global BurdenofDisease Study 2016.",JAMAoncology,Vol.4No.9,pp.1221-1227.

[0113] KUMAR,S.K.,RAJKUMAR,S.V.,DISPENZIERI,A.,LACY,M.Q.,HAYMAN,S.R.,BUADI,F.K.,ZELDENRUST,S.R.,DINGLI,D.,RUSSELL,S.J.,LUST,J.A.,GREIPP,P.R.,KYLE,R.A.&GERTZ,M.A.(2008),"Improved survival in multiple myeloma and the impact ofnovel therapies.",Blood,Vol.111No.5,pp.2516-20.

[0114] MAUDE,S.L.,LAETSCH,T.W.,BUECHNER,J.,RIVES,S.,BOYER,M.,BITTENCOURT,H.,BADER,P.,VERNERIS,M.R.,STEFANSKI,H.E.,MYERS,G.D.,QAYED,M.,DeMOERLOOSE,B.,HIRAMATSU,H.,SCHLIS,K.,DAVIS,K.L.,MARTIN,P.L.,NEMECEK,E.R.,YANIK,G.A.,PETERS,C.,BARUCHEL,A.,BOISSEL,N.,MECHINAUD,F.,BALDUZZI,A.,KRUEGER,J.,JUNE,C.H.,LEVINE,B.L.,WOOD,P.,TARAN,T.,LEUNG,M.,MUELLER,K.T.,ZHANG,Y.,SEN,K.,LEBWOHL,D.,PULSIPHER,M.A.&GRUPP,S.A.(2018),"Tisagenlecleucel in Children and YoungAdults with B-Cell Lymphoblastic Leukemia.",The New England journal ofmedicine,Vol.378No.5,pp.439-448.

[0115] MIKKILINENI,L.,MANASANCH,E.E.,LAM,N.,VANASSE,D.,BRUDNO,J.N.,MARIC,I.,ROSE,J.J.,STETLER-STEVENSON,M.,WANG,H.,YUAN,C.M.,STRONCEK,D.F.,MANN,J.,GANADAN,M.,PATEL,R.,TRINKLEIN,N.,BUELOW,B.,GRESS,R.E.&KOCHENDERFER,J.N.(2019),"T Cells Expressing an Anti-B-Cell Maturation Antigen(BCMA)ChimericAntigen Receptor with a Fully-Human Heavy-Chain-Only Antigen RecognitionDomain Induce Remissions in Patients with Relapsed Multiple Myeloma",Blood,Vol.1343230.

[0116] MUNSHI,N.C.,ANDERSON,L.D.J.,SHAH,N.,MADDURI,D.,BERDEJA,J.,LONIAL,S.,RAJE,N.,LIN,Y.,SIEGEL,D.,ORIOL,A.,MOREAU,P.,YAKOUB-AGHA,I.,DELFORGE,M.,CAVO,M.,EINSELE,H.,GOLDSCHMIDT,H.,WEISEL,K.,RAMBALDI,A.,REECE,D.,PETROCCA,F.,MASSARO,M.,CONNARN,J.N.,KAISER,S.,PATEL,P.,HUANG,L.,CAMPBELL,T.B.,HEGE,K.&SAN-MIGUEL,J.(2021),"Idecabtagene Vicleucel in Relapsed and RefractoryMultiple Myeloma.",The New England journal of medicine,Vol.384 No.8,pp.705-716.

[0117] OZAKI, S., HARADA, T., SAITOH, T., SHIMAZAKI, C., ITAGAKI, M., ASAOKU, H., KURODA, Y., CHOU, T., YOSH IKI,Y.,SUZUKI,K.,MURAKAMI,H.,HAYASHI,K.,ME,R.,PALUMBO,A.&SHIMIZU,K.(2014),"Survival of multiple myeloma patients aged 65-70years in the era of novel agents and autologous stem cell transplantation.Acta haematologica,Vol.132 No.2,pp.211-9.

[0118] RAJE,N.,BERDEJA,J.,LIN,Y.,SIEGEL,D.,JAGANNATH,S.,MADDURI,D.,LIEDTKE,M.,ROSENBLATT,J.,MAUS,MV,TURKA,A.,LAM,L.,MORGAN,RA,FRIEDMAN ,K.,MASSARO,M.,WANG,J.,RUSSOTTI,G.,YANG,Z.,CAMPBELL,T.,HEGE,K.,PETROCCA,F.,QUIGLEY,MT,MUNSHI,N.&KOCHENDERFER,JN(2019),"Anti-BCMA CAR T-Cell Therapy bb2121 inRelapsed or Refractory Multiple Myeloma.",The New Englandjournal ofmedicine,Vol.380 No.18,pp.1726-1737.

[0119] SCHUSTER,SJ,SVOBODA,J.,CHONG,EA,NASTA,SD,MATO,AR,SON, BROGDON,J.L.,PRUTEANU-MALINICI,I.,BHOJ,V.,LANDSBURG,D.,WASIK,M.,LEVINE,B.L.,LACEY,S.F.,MELENHORST,J.J.,PORTER,D.L.&JUNE,C.H.(2017),"Chimeric AntigenReceptor T Cells in Refractory B-Cell Lymphomas.",TheNewEnglandjournalofmedicine,Vol.377 No.26,pp.2545-2554.

[0120] TAI,Y.,MAYES,P.A.,ACHARYA,C.,ZHONG,M.Y.,CEA,M.,CAGNETTA,A.,CRAIGEN,J.,YATES,J.,GLIDDON,L.,FIELES,W.,HOANG,B.,TUNSTEAD,J.,CHRISTIE,A.L.,KUNG,A.L.,RICHARDSON,P.,MUNSHI,N.C.&ANDERSON,K.C.(2014),"Novel anti-B-cellmaturation antigen antibody-drug conjugate(GSK2857916)selectively induceskilling ofmultiple myeloma.",Blood,Vol.123No.20,pp.3128-38.

[0121] TURESSON,I.,VELEZ,R.,KRISTINSSON,S.Y.&LANDGREN,O.(2010),"Patterns ofimproved survival in patients with multiple myeloma in the twenty-firstcentury:a population-based study.",Journal of clinical oncology:officialjournal of the American Society of Clinical Oncology,Vol.28 No.5,pp.830-4.

[0122] TURTLE,C.J.,HAY,K.A.,HANAFI,L.,LI,D.,CHERIAN,S.,CHEN,X.,WOOD,B.,LOZANSKI,A.,BYRD,J.C.,HEIMFELD,S.,RIDDELL,S.R.&MALONEY,D.G.(2017),"DurableMolecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure ofIbrutinib.",Journal of clinical oncology:officialjournal of the AmericanSociety of Clinical Oncology,Vol.35 No.26,pp.3010-3020.

[0123] ZAH,E.,NAM,E.,BHUVAN,V.,TRAN,U.,JI,B.Y.,GOSLINER,S.B.,WANG,X.,BROWN,C.E.&CHEN,Y.Y.(2020),"Systematically optimized BCMA / CS1 bispecific CAR-Tcells robustly control heterogeneous multiple myeloma.",Naturecommunications,Vol.11 No.1,pp.2283.

Claims

1. A chimeric antigen receptor that simultaneously targets BCMA and CD38, characterized in that: The chimeric antigen receptor comprises the following elements: 1) Signal peptide region; 2) Anti-BCMA heavy chain region; 3) Linker 1; 4) Anti-BCMA light chain region; 5) Connector 2; 6) anti-CD38 antibody region; 8) Hinge region; 9) transmembrane region; 9) intracellular signaling co-stimulatory region; and 10) Intracellular signal stimulation area, Wherein, the amino acid sequence of the anti-CD38 antibody region is as shown in any one of SEQ ID NOs: 3-12, Wherein, the positions of the anti-BCMA heavy chain region and the anti-BCMA light chain region can be interchanged, And wherein, the positions of the anti-CD38 antibody region and the anti-BCMA antibody region containing the anti-BCMA heavy chain region, the anti-BCMA light chain and the linker can be interchanged.

2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the chimeric antigen receptor that simultaneously targets BCMA and CD38 as described in claim 1.

3. An expression vector, characterized in that The expression vector comprises the nucleic acid molecule of claim 2.

4. A recombinant lentivirus, characterized in that: The recombinant lentivirus comprises the nucleic acid molecule of claim 2 or is prepared by the expression vector of claim 3.

5. A method for preparing the recombinant lentivirus according to claim 4, characterized in that: The method comprises co-transfecting a mammalian host cell with the expression vector of claim 3 and a helper plasmid.

6. A method for preparing CAR-T cells that simultaneously target BCMA and CD38, characterized in that: The method comprises infecting T cells with the recombinant lentivirus of claim 4.

7. CAR-T cells targeting BCMA and CD38 simultaneously, characterized in that: The T cells are prepared by the method of claim 6.

8. A drug for treating a disease, characterized in that: The drug comprises the nucleic acid molecule of claim 2, the expression vector of claim 3, the recombinant lentivirus of claim 4 or the CAR-T cell of claim 7.

9. The disease treating drug according to claim 8, characterized in that: The disease is multiple myeloma, lymphoma, leukemia, systemic lupus erythematosus or Sjögren's syndrome.

10. Use of the nucleic acid molecule according to claim 2, the expression vector according to claim 3, the recombinant lentivirus according to claim 4 or the CAR-T cell according to claim 7 in a drug for treating a disease.

Images